Another study revealed that tumor biopsies from patients with metastatic melanoma undergoing treatment with a BRAF inhibitor, who progressed on therapy, showed a significant decrease in melanoma antigen expression at the time of progression through reactivation of the MAPK pathway [51]. This evidence concerns the gene BRAF and melanoma.